Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health ...
“Access to the PSPP program will advance our understanding and development of ART26.12,” commented Saoirse O’Sullivan, PhD, Vice President Translational Science at Artelo Biosciences. “We are most ...
Artelo Biosciences announces acceptance of ART26.12 into NIH PSPP program
Artelo Biosciences (ARTL) announced that ART26.12, the Company’s lead clinical FABP inhibitor, has been accepted into the NIH Helping to ...